69340-16-5

Upstream product

• 135103-27-4 C₁₆H₂₃NO₅*C₁₂H₂₃N 
• 91474-97-4 methyl O,N-dimethyl-N-boc-L-tyr-L-alaninate 
• 73584-84-6 (S)-2-(tert-butoxycarbonyl(methyl)amino)-3-(4-methoxyphenyl)propanoic acid 
• 115441-65-1 methyl N-Cbz-N,O-dimethyl-L-tyrosyl-L-alaninate 
• 115441-64-0 methyl N-Cbz-N-methyl-L-tyrosyl-L-alaninate 
• 86099-14-1 (2S)-3-(4-hydroxyphenyl)-2-(methyl{[(phenylmethyl)oxy]carbonyl}amino)propanoic acid 
• 91474-98-5 methyl O,N-dimethyl-L-tyr-L-alaninate 
• 91475-00-2 methyl N-boc-L-ala-O,N-dimethyl-L-tyr-L-alaninate 

Downstream Products

• 91475-01-3 methyl N-boc-D-ala-L-ala-O,N-dimethyl-L-tyr-L-alaninate 
• 675129-45-0 Boc-Gly-Ala-N,O-dimethyl-Tyr-Ala-OH 
• 122546-77-4 12-({2-[2-{[2-(2-amino-acetylamino)-propionyl]-methyl-amino}-3-(4-methoxy-phenyl)-propionylamino]-propionyl}-methyl-amino)-4-methoxy-10-methyl-11-oxo-2-oxa-10-aza-tricyclo[12.2.2.1^3,7]nonadeca-1⁽¹⁷⁾,3⁽¹⁹⁾,4,6,14⁽¹⁸⁾,15-hexaene-9-carboxylic acid 
• 675129-57-4 C₄₇H₅₆N₆O₁₀ 
• 675129-54-1 C₅₂H₆₄N₆O₁₂ 
• 1372157-31-7 [Tyr-5-ψ(CH2NMe)-Tyr-6]RA-VII 
• 1372157-33-9 C₅₃H₆₈N₆O₁₁ 
• 112196-84-6 BOC-D-Ala-L-Ala-NMe-L-Tyr(OMe)-L-Ala-OH 
• 138571-40-1 C₄₅H₅₈N₆O₁₂ 
• 91475-02-4 methyl N-boc-N-methyl-L-tyr-N-methyl-L-tyr-D-ala-L-ala-O,N-dimethyl-L-tyr-L-alaninate 
• 91502-35-1 methyl N-methyl-L-tyr-N-methyl-L-tyr-D-ala-L-ala-O,N-dimethyl-L-tyr-L-alaninate 
• 91474-95-2 methyl D-ala-L-ala-O,N-dimethyl-L-tyr-L-alaninate 
• 91502-34-0 cyclo-N-methyl-L-tyr-N-methyl-L-tyr-D-ala-L-ala-O,N-dimethyl-L-tyr-L-ala 
• 675129-44-9 Boc-Gly-Ala-N,O-dimethyl-Tyr-Ala-OMe 

Relevant academic research and scientific papers

BOUVARDIN DERIVATIVES AND THERAPEUTIC USES THEREOF

The present invention is directed at bouvardin analogs arid related compounds for the treatment of disorders including cancer. Provided herein are bouvardin analogs and related compounds, pharmaceutical compositions and kits comprising at least one bouvar

Synthesis of [Tyr-5-Ψ(CH2NMe)-Tyr-6]RA-VII, a reduced peptide bond analogue of RA-VII, an antitumor bicyclic hexapeptide

A reduced peptide bond analogue of RA-VII, [Tyr-5-Ψ(CH 2NMe)-Tyr-6]RA-VII (3), was designed and synthesized. The key reduced cycloisodityrosine unit was prepared by reduction of the cycloisodityrosine derived from natural RA-VII, followed by co

Synthesis of [Gly-1]RA-VII, [Gly-2]RA-VII, and [Gly-4]RA-VII. Glycine-Containing Analogues of RA-VII, an Antitumor Bicyclic Hexapeptide from Rubia Plants

Three analogues of RA-VII (1), an antitumor bicyclic hexapeptide from Rubia plants, were synthesized. Three analogues, [Gly-1]RA-VII (4), [Gly-2]RA-VII (5), and [Gly-4]RA-VII (6), in which one of the three alanine residues in 1 was replaced by a glycine r

SYNTHESIS OF CYCLO-N-METHYL-L-TYR-N-METHYL-L-TYR-D-ALA-L-ALA-O,N-DIMETHYL-L-TYR-L-ALA, A CYCLIC HEXAPEPTIDE RELATED TO THE ANTITUMOR AGENT DEOXYBOUVARDIN

A synthesis of the title cyclic hexapeptide is described.Its lack of antitumor activity shows that the 14-membered ring of deoxybouvardin is needed for activity.Efforts to oxidatively its phenolic groups failed to give deoxybouvardin.